SUBSCRIBE
SUBSCRIBE
News   Business

Crucell N.V., DSM Biologics Sign PER.C6 License Agreement with Daiichi Sankyo, Inc.

November 16, 2007 | 
1 min read
AMSTERDAM, Nov. 16, 2007 (Thomson Financial delivered by Newstex) -- Crucell (NASDAQ:CRXL) NV and Royal DSM NV's (OOTC:RDSMY) DSM Biologics said they have signed a license agreement with Daiichi Sankyo Company Limited.
Alliances Europe
Daiichi Sankyo
MORE ON THIS TOPIC
Handmade signboard with Closed inscription and striped rope hanging on pin on bright red background
Company closure
Bespoke Startup EveryONE Folds 1 Week After Plausible Mechanism Guidance
March 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Theravance Halves Headcount, Cans R&D Work After Phase 3 Fail
March 4, 2026
 · 
61 min read
 · 
BioSpace Editorial Staff
Halftone hands reaching for money. Mixed media catch falling coins and cash bills collage, financial success, free wealth and easy money concept vector illustration
Earnings
Keytruda Hangs On to Best Seller Crown as GLP-1s Gain Ground
March 4, 2026
 · 
9 min read
 · 
Tristan Manalac
Set of crumpled lumps of different paper isolated on yellow background. Gritty dusty dotted effect, vector elements with jagged edges, old notebook sheets.
MASH
Boehringer Ingelheim Axes MASH Pact With OSE After Disappointing Mid-Stage Data
March 3, 2026
 · 
2 min read
 · 
Tristan Manalac